Candriam S.C.A. Zentalis Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$41.58 - $80.89 $343,159 - $667,585	-8,253 Reduced 6.06%	127,973 $5.9 Million
Q4 2021 Feb 10, 2022	SELL	$66.92 - $84.79 $4.84 Million - $6.13 Million	-72,300 Reduced 34.67%	136,226 $11.5 Million
Q2 2021 Jul 20, 2021	BUY	$37.41 - $62.25 $7.8 Million - $13 Million	208,515 Added 1895590.88%	208,526 $11.1 Million
Q1 2021 Apr 29, 2021	BUY	$35.69 - $52.72 $392 - $579	11 New	11 $0

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.